

TECHNICAL NOTE

Mario E. Alburges,¹ B.S. and Michael A. Peat,² Ph.D.

Profiles of Δ^9 -Tetrahydrocannabinol Metabolites in Urine of Marijuana Users: Preliminary Observations by High Performance Liquid Chromatography-Radioimmunoassay

REFERENCE: Alburges, M. and Peat, M. A., "Profiles of Δ^9 -Tetrahydrocannabinol Metabolites in Urine of Marijuana Users: Preliminary Observations by High Performance Liquid Chromatography-radioimmunoassay," *Journal of Forensic Sciences*, JFSCA, Vol. 31, No. 2, April 1986, pp. 695-706.

ABSTRACT: Metabolic profiles of 11-nor-9-carboxylic acid- Δ^9 -tetrahydrocannabinol (COOH-THC) and other THC metabolites were determined in an infrequent and a frequent marijuana user by high performance liquid chromatography-radioimmunoassay (HPLC-RIA). In the infrequent user, no unconjugated COOH-THC was detected in urine samples for the first 8 h following smoking, whereas this metabolite was detected in the urine samples from a frequent user. A metabolite was also detected in the frequent user, which was not present in the urine sample from the infrequent user.

KEYWORDS: toxicology, tetrahydrocannabinol, marijuana, chromatographic analysis, urine

The major metabolic pathway of Δ^9 -tetrahydrocannabinol (Δ^9 -THC) involves cytochrome P450-mediated hydroxylation of the allylic methyl group (position C-11 based on dibenzopyran numbering system) followed by conversion to 11-nor-9-carboxylic acid- Δ^9 -THC (COOH-THC). Glucuronide conjugates of THC and its metabolites can be formed at the carboxylic acid group (position C-11) [1], or the phenolic group (position C-1) [2]. In the case of COOH-THC, conjugation may occur at both sites. The major metabolites in both blood and urine have been reported to be COOH-THC and its glucuronide conjugates [3,4].

A variety of analytical techniques have been used to measure Δ^9 -THC and its metabolites in biological fluids, such as immunoassay [5], thin-layer chromatography (TLC) [6], gas chromatography (GC) [7,8], gas chromatography-mass spectrometry (GC-MS) [9], high performance liquid chromatography (HPLC) [10,11], and HPLC-radioimmunoassay (HPLC-RIA) [12,13]. This last procedure has two advantages, first the lack of sensitivity obtained using HPLC with ultraviolet wavelength detection is overcome by using a sensitive immu-

Received for publication 20 April 1985; accepted for publication 10 Aug. 1985.

¹Graduate student, Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT.

²Codirector, Chemical Toxicology, Institute, Foster City, CA.

noassay procedure, and second, the lack of specificity of certain antisera is overcome by using a chromatographic separation.

The present study was designed to characterize the urinary profiles of Δ^9 -THC metabolites under controlled conditions. Although other workers [12, 13] have reported on such profiles, the urine samples were not collected under controlled conditions. In addition, the profiles described in this study were compared in frequent and infrequent marijuana users. For the purposes of this study an infrequent user was a person who smoked marijuana on average twice a month and a frequent user one who used marijuana daily.

Materials

A Varian Model 5020 liquid chromatograph equipped with a Varian UV-5 detector set at 215 nm (Varian Instrument Co., Walnut Creek, CA) was used for all HPLC assays. A Spherisorb-ODS (5 μ m), 10-cm by 4.6-mm HPLC column was used (Supelco Inc., Bellefonte, PA). Eluent fractions were collected using a Buchler LC 100 fraction collector. All the solvents used were HPLC grade; all other chemicals were reagent grade. β -glucuronidase (341 000 U/g) was purchased from Sigma Chemical Co., St. Louis, MO. RIA analysis was performed using the Abuscreen[®] procedure for cannabinoids (Roche Diagnostics, Nutley, NJ).

Samples of Δ^9 -THC, 11-hydroxy- Δ^9 -THC (OH-THC), 8α , 11-dihydroxy- Δ^9 -THC (8α , 11-OH-THC), and COOH-THC were supplied by the National Institute on Drug Abuse. A small sample of 8α -hydroxy- Δ^9 -THC (8α -OH-THC) was generously supplied by Dr. El Sohly, University of Mississippi.

Methods

Each subject smoked a single marijuana cigarette, containing 1.8% THC at 8:00 p.m. They were asked not to smoke after midnight of the night before the test session. The infrequent user had not smoked in the previous five weeks. The frequent user had smoked at least one cigarette in the previous 24 h, but none within 12 h of testing. The frequent user was a daily user of marijuana. Both subjects were instructed to smoke in their usual manner except that the cigarette had to be smoked so that a 8-mm butt remained. Urine samples were collected over a 14-day period.

The HPLC procedure used was that of Peat et al [12] with one minor modification; the urine sample was adjusted to pH 3.0 with hydrochloric acid before injection. Briefly, 2 mL of urine are mixed with 2 mL of methanol and 2 mL of methanol: water (1:1) adjusted to pH 3.0 with 1N hydrochloric acid. After centrifuging, 5 mL of the supernatant are injected via a 5-mL injection loop directly onto the HPLC column. The mobile phase is acetonitrile: water (adjusted to pH 3.3 with phosphoric acid); the following gradient is used: 0 to 10 min—36% acetonitrile; 10 to 20 min—36 to 70% acetonitrile, and 20 to 25 min—70% acetonitrile. The flow rate is 4 mL per min and fractions are collected every 30 s; the first four fractions are discarded. Each fraction collected is evaporated to dryness at 40°C under vacuum using a Buchler vortex evaporator. Radioimmunoassay was carried out on each fraction, according to the manufacturer's instructions, after dissolving the residue in 100 μ L of drug-free urine. For experiments involving hydrolysis, urine was incubated with β -glucuronidase (5000 units per mL of urine) at 37°C overnight after adjustment to pH 5.0 with 1.0M sodium acetate.

Standards of COOH-THC ranging from 5.0 to 75 ng/mL were prepared in drug-free urine and analyzed by the above procedure to estimate the relative concentration (ng/mL) of cross-reacting cannabinoids (CRC).

Results

Figure 1 shows an HPLC-ultraviolet (UV) chromatogram of Δ^9 -THC and metabolites, the retention volumes are as follows: 8α , 11 -OH-THC: 22 mL; 8α -OH-THC: 44 mL; OH-THC: 54 mL; COOH-THC: 59 mL; and THC: 79 mL.

Figure 2 illustrates HPLC-RIA chromatograms of urine samples collected from an infrequent user 2 and 4 h after smoking a marijuana cigarette containing 1.8% THC. Only the sample collected at 4 h contained detectable amounts of unconjugated COOH-THC, none of the other samples collected up to 8 h after smoking contained unconjugated COOH-THC. A peak (identified as I in Fig. 2) was found in samples collected between 1 and 8 h after smoking. The retention volume of the peak was similar to 8α , 11 -OH-THC. In each of these unhydrolyzed samples appreciable amounts of cross-reacting cannabinoids were found in an early eluting fraction (retention volume no greater than 12 mL).

Figure 3 shows HPLC-RIA chromatograms of the same urine samples after hydrolysis with β -glucuronidase; significant differences were seen. In the samples collected for up to 8 h after smoking, appreciable amounts of COOH-THC were detected (range of CRC was 25 to 73 ng/mL). In three of the samples, those collected between 1 and 4 h, a new peak appeared (identified as II) in the chromatograms. The concentration of this peak reached a maximum




FIG. 1—An HPLC-UV chromatogram of 8α , 11 -OH-THC, 8α -OH-THC, 11 -OH-THC, COOH-THC, and THC. For conditions see Methods section.




FIG. 2—HPLC-RIA chromatograms of urine samples collected from an infrequent user 2 and 4 h after smoking a marijuana cigarette containing 1.8% THC.




FIG. 3—HPLC-RIA chromatograms of enzyme hydrolyzed urine samples collected from an infrequent user 2 and 4 h after smoking a marijuana cigarette containing 1.8% THC.

(15-ng/mL CRC) 2 h after smoking. I, which was detected in the unhydrolyzed samples, was also detected in the hydrolyzed samples at lower concentrations. In all of the enzyme hydrolyzed samples, the amount of CRC detected in the early eluting fraction was dramatically decreased. Figure 4 shows the concentrations of CRC detected in the fractions corresponding to COOH-THC, I and II in the urine samples collected for up to 8 h after smoking in an infrequent user.

Figures 5, 6, and 7 show the corresponding data for samples from a frequent user. As can be seen, there are significant differences from the infrequent user chromatograms. First, between 17 and greater than 75 ng/mL of CRC were detected in the COOH-THC fraction of unhydrolyzed urine, with a peak being noted 1 h after smoking. I was also observed in these urine samples, but in this instance 42-ng/mL CRC of I was still detectable 24 h after smoking. Of interest, a new fraction (identified as III) was found in the urine samples from frequent marijuana smokers; this reached a peak of 15 ng/mL 2 h after smoking. The retention volume (38 mL) of this fraction was slightly lower than that of 8 α -OH-THC. Similarly to the infrequent user significant amounts of CRC were detected in an early eluting fraction.

After enzyme hydrolysis a more complex HPLC-RIA chromatogram was observed (Fig. 6). However, similar trends to those seen in the urine samples from an infrequent user were apparent. There was a significant reduction in the amount of CRC detected in the early eluting fraction and an increase in the CRC detected in the COOH-THC fraction, with a peak concentration of greater than 75 ng/mL being detected in the latter fraction 2 h after smoking. I was also detected in these hydrolyzed samples, although at lower concentrations than in the unhydrolyzed samples. II appeared after hydrolysis with a peak concentration of 55-ng/mL CRC after 2 h. III, which was not detected in the urine samples from an infrequent user, increased in concentration after hydrolysis of urine samples from a frequent user. Figure 7 summarizes the time-course data for the samples from the frequent user.




FIG. 4—Concentrations of cross-reacting cannabinoids (CRC ng/mL) in the HPLC-RIA fractions corresponding to COOH-THC, I and II in an infrequent user.




FIG. 5—HPLC-RIA chromatograms of urine samples collected from a frequent user 2 and 4 h after smoking a marijuana cigarette containing 1.8% THC.




FIG. 6—HPLC-RIA chromatograms of enzyme hydrolyzed urine samples collected from a frequent user 2 and 4 h after smoking a marijuana cigarette containing 1.8% THC.




FIG. 7—Concentrations of cross-reacting cannabinoids (CRC ng/mL) in the HPLC-RIA fractions corresponding to COOH-THC, I, II, and III.

Discussion

The data reported here should be considered to be preliminary observations for three reasons. First the study involved only one frequent and one infrequent marijuana user and the results should be confirmed by examining more urine samples. Second, although the differences seen appear to be qualitative, they may only be quantitative because the sensitivity of the HPLC-RIA assay used was equivalent to 5 ng/mL of COOH-THC. Third, the exact identification of I, II, and III has not been determined. However, several of our findings may be of importance to forensic toxicologists.

Most importantly, it appears that in infrequent users virtually all the COOH-THC excreted in the first 8 h is in the conjugated form. This supports the suggestion of Law et al [4] who reported that following the oral administration of THC the glucuronide conjugate of COOH-THC was the major metabolite detected in plasma and urine. However, this does not apply to frequent users as significant concentrations of unconjugated COOH-THC were detected in urine samples from this group. Our data do suggest that there may be a metabolite present in the urine of frequent marijuana users which is not found in that of infrequent users. In this report, metabolite is indicated as III and has a retention volume similar to 8α -OH-THC. It would also appear that it forms a glucuronide conjugate because hydrolysis of the urine with β -glucuronidase results in an increase in its concentration.

The dramatic difference observed in the excretion of unconjugated COOH-THC between the frequent and infrequent user may be due to several reasons. First, heavy use of marijuana by the frequent user may have resulted in a saturation of the hepatic glucuronyl transferase system responsible for conjugation. This enzyme system may also have been altered by use of other drugs in this individual, although he admitted only to frequent use of marijuana and ethanol and occasional use of cocaine. Metabolites of THC are also excreted in the feces

and it is possible that a switch of excretion pathways in the frequent user is responsible for the urinary excretion of unconjugated COOH-THC.

In both sets of urine samples significant concentrations of CRC were detected in an early eluting fraction; because of the reversed-phase HPLC system used this fraction is assumed to contain conjugates of either carboxylic acid or phenolic metabolites. After hydrolysis with β -glucuronidase there was a significant increase in the COOH-THC fraction and a decrease in the early eluting fraction as would be expected if the early eluting fraction was primarily glucuronide conjugates. I and II were also found in urine samples from infrequent and frequent users. I, which has a retention volume similar to 8α , 11-OH-THC, decreased in concentration following β -glucuronidase hydrolysis, whereas II was only present after hydrolysis. This suggests that II is an unconjugated form of a conjugate detected in the early eluting fraction or in I; although the latter also contains other CRC because it is only reduced by approximately 25% following hydrolysis.

The time period over which unconjugated COOH-THC and I can be detected differs between the users. In fact, in an infrequent user, unconjugated COOH-THC is detected at very low concentrations in only one of the urine specimens, whereas in a frequent user it is detected for at least 24 h. Although I is detected in both sets of urine samples, it is found for only 4 to 8 h in the infrequent user at appreciable concentrations, but for at least 24 h in a frequent user.

From our data it appears as if I contains at least two compounds, possibly a glucuronide conjugate of II and a dihydroxy metabolite of THC. In addition, III, which was detected in frequent users, also appears to form a glucuronide conjugate. This data would suggest therefore that II and III form glucuronide conjugates at either the C-11 carboxylic acid or the C-1 phenolic group. Haldin et al [14] have reported that apart from COOH-THC two other carboxylic acid metabolites can be detected in urine samples from marijuana users at greater than trace amounts. The structures and abundances of these three metabolites are shown in Fig. 8 and Table 1. II and III may, therefore, be these metabolites; however, the study of




FIG. 8—Structures of the three major carboxylic metabolites in urine.

TABLE 1—Relative abundances of the three major carboxylic metabolites in urine.

Metabolite	R ₁	R ₂	R ₃	% of Total Excreted ^a
11-Nor-delta-9-carboxylic acid (COOH-THC)	COOH	H	C ₅ H ₁₁	27
4', 5'-Bisno-delta-9-11,4'-dicarboxylic acid	COOH	H	C ₂ H ₄ COOH	8
4'-Hydroxy-delta-9-11-carboxylic acid	COOH	H	C ₅ H ₁₀ OH	5

^aOver 72 h after last administered dose [14].

Haldin et al [14] was limited to identifying acidic metabolites and the possibility exists that II and III do not contain a carboxylic acid grouping and may simply form glucuronide conjugates on the phenolic position alone.

In summary, this study has demonstrated two differentiating characteristics between frequent and infrequent users; one is that in the former the COOH-THC is excreted as glucuronide conjugates and that a metabolite III is detectable only in urine samples from a frequent user. With the difficulty in interpreting blood or plasma THC and metabolite concentrations these findings may assist in the identification of the type of user involved, although it should be remembered that the users studied here represent extremes in their frequency of use. Further investigations are in progress to identify these metabolites and to elucidate the reasons for the differences.

Acknowledgment

This publication was supported by the Insurance Institute for Highway Safety. The opinion, findings, and conclusions expressed in this publication are those of the author(s) and do not necessarily reflect the views of the Insurance Institute for Highway Safety.

M. Alburges was supported by a grant from the University of Zulia School of Medicine, Maracaibo, Venezuela.

References

- [1] Williams, P. L. and Moffat, A. C., "Identification in Human Urine of Δ^9 -Tetrahydrocannabinol-11-oic Acid Glucuronide: A Tetrahydrocannabinol Metabolite," *Journal of Pharmacy and Pharmacology*, Vol. 31, 1980, pp. 445-448.
- [2] Pallante, S., Lyle, M. A., and Fenselau, C., "Synthesis and Characterization of Glucuronides of 5'-Hydroxy-Delta-9-THC and 11-Hydroxy-Delta-9-THC," *Drug Metabolism and Disposition*, Vol. 6, 1978, pp. 389-395.
- [3] Peat, M. A., McGinnis, K. M., Johnson, J. R., Galinsky, R. E., Foltz, R. L., and Jones, R. T., "The Disposition of Δ^9 -Tetrahydrocannabinol, 11-Hydroxy- Δ^9 -Tetrahydrocannabinol and 11-Nor-9-Carboxylic Acid- Δ^9 -Tetrahydrocannabinol in Frequent and Infrequent Marijuana Users," *Journal of Pharmacology and Experimental Therapeutics*.
- [4] Law, B., Mason, P. A., Moffat, A. C., Gleadle, R. I., and King, L. J., "Forensic Aspects of the Metabolism and Excretion of Cannabinoids following Oral Ingestion of Cannabis Resin," *Journal of Pharmacology and Pharmacology*, Vol. 36, 1983, pp. 289-294.
- [5] Peat, M. A., "The Analysis of Δ^9 -Tetrahydrocannabinol and its Metabolites by Immunoassay," in *Advances in Analytical Toxicology*, Vol. 1, R. C. Baselt, Ed., Biomedical Publications, Foster City, CA, 1984, pp. 59-80.
- [6] Kanter, S. L., Hollister, L. E., and Zamora, J. U., "Marijuana Metabolites in Urine of Man XI. Detection of Unconjugated and Conjugated Δ^9 -Tetrahydrocannabinol-11-oic Acid by Thin Layer Chromatography," *Journal of Chromatography*, Vol. 235, 1982, pp. 507-512.
- [7] Whiting, J. D. and Mandrs, W. W., "Confirmation of a Tetrahydrocannabinol Metabolite in Urine by Gas Chromatography," *Journal of Analytical Toxicology*, Vol. 6, 1982, pp. 49-52.
- [8] El Sohly, M. A., Arafat, E. S., and Jones, A. B., "Analysis of the Major Metabolite Δ^9 -Tetrahydrocannabinol in Urine. III. A GC/ECD Procedure," *Journal of Analytical Toxicology*, Vol. 8, 1984, pp. 7-9.
- [9] Foltz, R. L., "Analysis of Cannabinoids in Physiological Specimens by Gas Chromatography/Mass Spectrometry," in *Advances in Analytical Toxicology*, Vol. 1, R. C. Baselt, Ed., Biomedical Publications, Foster City, CA, 1984, pp. 125-157.
- [10] El Sohly, M. A., El Sohly, H. N., Jones, A. B., Dimson, P. A., and Wells, K. E., "Analysis of the Major Metabolite of Δ^9 -Tetrahydrocannabinol in Urine. II. A HPLC Procedure," *Journal of Analytical Toxicology*, Vol. 7, 1983, pp. 262-264.
- [11] Posey, B. L. and Kimble, S. N., "Quantitative Determination of 11-Nor- Δ^9 -Tetrahydrocannabinol and its Metabolites in Urine by HPLC," *Journal of Analytical Toxicology*, Vol. 8, 1984, pp. 234-238.
- [12] Peat, M. A., Deyman, M. E., and Johnson, J. R., "High Performance Liquid Chromatography-Immunoassay of Δ^9 -Tetrahydrocannabinol and Its Metabolites in Urine," *Journal of Forensic Sciences*, Vol. 29, No. 1, Jan. 1984, pp. 110-119.
- [13] Law, B., Mason, P. A., Moffat, A. C., and King, L. J., "Confirmation of Cannabis Use by the

- Analysis of Δ^9 -Tetrahydrocannabinol Metabolites in Blood and Urine by Combined HPLC and RIA," *Journal of Analytical Toxicology*, Vol. 8, 1984, pp. 19-22.
- [14] Halldin, M. M., Widman, M., Agurell, S., Hollister, L. E., and Kanter, S. L., "Acidic Metabolites of Delta-1-Tetrahydrocannabinol Excreted in the Urine of Man," in *The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects*, S. Agurell, W. L. Dewey, and R. E. Willette, Eds., Academic Press, New York, 1984, pp. 221-218.

Address requests for reprints or additional information to
Michael A. Peat, Ph.D.
Chemical Toxicology Institute
P.O. Box 8209
1167 Chess Dr., Suite E
Foster City, CA 94404